Mantle Cell Lymphoma (MCL) research at the University of Texas MD Anderson Cancer Center is set to receive a major philanthropic contribution. Philanthropists Rich and Nancy Kinder’s Kinder Foundation have donated $1 million in funding for the research institution to bolster their efforts to study the disease.
Because MCL is a relatively rare form of cancer, part of the aggressive B-cell subtype of non-Hodgkin lymphoma, it tends to go somewhat underfunded compared to other more widespread forms of cancer, such as breast cancer. However, about 3,500 people are diagnosed with the disease annually, and as more than 90 percent of the diagnoses are late-stage, the prognoses tend to be quite poor in those diagnosed with the disease. For this reason, the Kinder Foundation sees value in investing such a large amount of resources into Mantle Cell Lymphoma research.
Dr. Michael Wang, professor in lymphoma/myeloma and director of MD Anderson’s MCL Program of Excellence, is set to lead the newly-funded Mantle Cell Lymphoma research initiative, which will be in part to advance research on the cancer-fighting drug ibrutinib.
Of course, the drug ibrutinib has made its way into cancer research news consistently for some time now. In September, BioNews Texas reported on Dr. Wang’s impressive Mantle Cell Lymphoma research involving the drug. Back in June of 2013, we also reported on how two studies of Ibrutinib in patients with Relapsed/Refractory Mantle Cell Lymphoma (MCL) and Chronic Lymphocytic Leukemia (CLL) revealed both efficiency and safety — also associated with MD Anderson.
Nancy Kinder, president of the Kinder Foundation and a senior member of MD Anderson’s Board of Visitors, sees the funding as well placed among the researchers at MD Anderson, given the Center’s proven leadership in cutting-edge cancer research: “MD Anderson is on the forefront of cancer research, and we believe the work of Dr. Wang will lead to more effective treatment, patient care and outcomes for MCL patients.”
Photo from Wikipedia.org